Monday, March 17, 2025 | 03:03 AM ISTहिंदी में पढें
Business Standard
Notification Icon
userprofile IconSearch

How a dosing error turned into lucky punch for AstraZeneca and Oxford

"The reason we had the half-dose is serendipity," Mene Pangalos, the head of AstraZeneca's non-oncology research and development, told Reuters

Photo: Reuters
Premium

Photo: Reuters

Ludwig Burger and Kate Kelland | Reuters Frankfurt/London
A stroke of good fortune from a dosing error will pave the way for AstraZeneca and Oxford University to submit their Covid-19 vaccine for regulatory clearance.

The British drugmaker said on Monday that the vaccine could be around 90% effective, when administered as a half dose followed by a full dose a month later, citing data from late-stage trials in Britain and Brazil.

"The reason we had the half-dose is serendipity," Mene Pangalos, the head of AstraZeneca's non-oncology research and development, told Reuters.

A larger group who had received two full doses - as planned - resulted in an efficacy read-out

What you get on BS Premium?

  • Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
  • Pick your 5 favourite companies, get a daily email with all news updates on them.
  • Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
  • Preferential invites to Business Standard events.
  • Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in